149 related articles for article (PubMed ID: 38376229)
1. A population pharmacokinetic model for posaconazole intravenous solution and oral powder for suspension formulations in pediatric patients with neutropenia.
Winchell G; de Greef R; Ouerdani A; Fauchet F; Wrishko RE; Mangin E; Bruno C; Waskin H
Antimicrob Agents Chemother; 2024 Apr; 68(4):e0119723. PubMed ID: 38376229
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and safety of posaconazole intravenous solution and powder for oral suspension in children with neutropenia: an open-label, sequential dose-escalation trial.
Groll AH; Abdel-Azim H; Lehrnbecher T; Steinbach WJ; Paschke A; Mangin E; Winchell GA; Waskin H; Bruno CJ
Int J Antimicrob Agents; 2020 Sep; 56(3):106084. PubMed ID: 32682946
[TBL] [Abstract][Full Text] [Related]
3. Model Based Estimation of Posaconazole Tablet and Suspension Bioavailability in Hospitalized Children Using Real-World Therapeutic Drug Monitoring Data in Patients Receiving Intravenous and Oral Dosing.
Kane Z; Cheng I; McGarrity O; Chiesa R; Klein N; Cortina-Borja M; Standing JF; Gastine S
Antimicrob Agents Chemother; 2023 Jul; 67(7):e0007723. PubMed ID: 37260401
[TBL] [Abstract][Full Text] [Related]
4. A Population Pharmacokinetic Model for a Solid Oral Tablet Formulation of Posaconazole.
van Iersel MLPS; Rossenu S; de Greef R; Waskin H
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29712663
[TBL] [Abstract][Full Text] [Related]
5. A Population Pharmacokinetic Modeling and Simulation Study of Posaconazole Oral Suspension in Immunocompromised Pediatric Patients: A Short Communication.
Elkayal O; Spriet I; Uyttebroeck A; Colita A; Annaert P; Allegaert K; Smits A; Van Daele R; Dreesen E
Ther Drug Monit; 2021 Aug; 43(4):512-518. PubMed ID: 33560094
[TBL] [Abstract][Full Text] [Related]
6. An Integrated Population Pharmacokinetic Analysis for Posaconazole Oral Suspension, Delayed-Release Tablet, and Intravenous Infusion in Healthy Volunteers.
Chen L; Krekels EHJ; Heijnen AR; Knibbe CAJ; Brüggemann RJ
Drugs; 2023 Jan; 83(1):75-86. PubMed ID: 36607589
[TBL] [Abstract][Full Text] [Related]
7. Population Pharmacokinetics of Posaconazole in Immune-Compromised Children and Assessment of Target Attainment in Invasive Fungal Disease.
McCann S; Sinha J; Wilson WS; McKinzie CJ; Garner LM; Gonzalez D
Clin Pharmacokinet; 2023 Jul; 62(7):997-1009. PubMed ID: 37179512
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and Safety of Posaconazole Administered by Intravenous Solution and Oral Tablet in Healthy Chinese Subjects and Effect of Food on Tablet Bioavailability.
Li H; Wei Y; Zhang S; Xu L; Jiang J; Qiu Y; Mangin E; Zhao XM; Xie S
Clin Drug Investig; 2019 Nov; 39(11):1109-1116. PubMed ID: 31432392
[TBL] [Abstract][Full Text] [Related]
9. Initial posaconazole dosing to achieve therapeutic serum posaconazole concentrations among children, adolescents, and young adults receiving delayed-release tablet and intravenous posaconazole.
Bernardo V; Miles A; Fernandez AJ; Liverman R; Tippett A; Yildirim I
Pediatr Transplant; 2020 Sep; 24(6):e13777. PubMed ID: 32639095
[TBL] [Abstract][Full Text] [Related]
10. Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease.
Cornely OA; Duarte RF; Haider S; Chandrasekar P; Helfgott D; Jiménez JL; Candoni A; Raad I; Laverdiere M; Langston A; Kartsonis N; Van Iersel M; Connelly N; Waskin H
J Antimicrob Chemother; 2016 Mar; 71(3):718-26. PubMed ID: 26612870
[TBL] [Abstract][Full Text] [Related]
11. A non-randomized trial to assess the safety, tolerability, and pharmacokinetics of posaconazole oral suspension in immunocompromised children with neutropenia.
Arrieta AC; Sung L; Bradley JS; Zwaan CM; Gates D; Waskin H; Carmelitano P; Groll AH; Lehrnbecher T; Mangin E; Joshi A; Kartsonis NA; Walsh TJ; Paschke A
PLoS One; 2019; 14(3):e0212837. PubMed ID: 30913226
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of Posaconazole Oral Suspension in Children Dosed According to Body Surface Area.
Vanstraelen K; Colita A; Bica AM; Mols R; Augustijns P; Peersman N; Vermeersch P; Annaert P; Spriet I
Pediatr Infect Dis J; 2016 Feb; 35(2):183-8. PubMed ID: 26544987
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics of posaconazole in Chinese pediatric patients with acute leukaemia: Effect of food on bioavailability and dose optimization.
Lin D; Yu L; Shang D; Huang L; Wu L; Liao X; Zhang Y; Zi J; Zhang J; Zeng Y; Wang X; Yang L
Eur J Pharm Sci; 2022 Nov; 178():106289. PubMed ID: 36041707
[TBL] [Abstract][Full Text] [Related]
14. Evaluating posaconazole dosing regimens of the different formulations against Aspergillus spp. in adults: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation.
Wei XC; Zhao MF; Li X; Xiao X
Int J Antimicrob Agents; 2020 Oct; 56(4):106112. PubMed ID: 32721598
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease.
Cornely OA; Robertson MN; Haider S; Grigg A; Geddes M; Aoun M; Heinz WJ; Raad I; Schanz U; Meyer RG; Hammond SP; Mullane KM; Ostermann H; Ullmann AJ; Zimmerli S; Van Iersel MLPS; Hepler DA; Waskin H; Kartsonis NA; Maertens J
J Antimicrob Chemother; 2017 Dec; 72(12):3406-3413. PubMed ID: 28961714
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and Safety of Posaconazole Tablet Formulation in Chinese Participants at High Risk for Invasive Fungal Infection.
Liu K; Wu D; Li J; Chen H; Ning H; Zhao T; Dai H; Chen L; Mangin E; Winchell GA; Waskin H; Jiang J; Qiu Y; Zhao XM
Adv Ther; 2020 May; 37(5):2493-2506. PubMed ID: 32319040
[TBL] [Abstract][Full Text] [Related]
17. Phase 1b/3 Pharmacokinetics and Safety Study of Intravenous Posaconazole in Adult Asian Participants at High Risk for Invasive Fungal Infections.
Wu D; Mi Y; Weng J; Zhuang J; Ke X; Wang C; Liu K; Martinho M; Winchell GA; Zang Y; Xu L
Adv Ther; 2022 Apr; 39(4):1697-1710. PubMed ID: 35167031
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease.
Krishna G; Martinho M; Chandrasekar P; Ullmann AJ; Patino H
Pharmacotherapy; 2007 Dec; 27(12):1627-36. PubMed ID: 18041883
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome.
Krishna G; AbuTarif M; Xuan F; Martinho M; Angulo D; Cornely OA
Pharmacotherapy; 2008 Oct; 28(10):1223-32. PubMed ID: 18823218
[TBL] [Abstract][Full Text] [Related]
20. Model-Informed Dose Justifications of Posaconazole in Japanese Patients for Prophylaxis and Treatment Against Fungal Infection.
Iwasa T; de Almeida C; Fauchet F; Winchell GA; de Greef R; Hasegawa C; Yoshitsugu H; Wrishko RE
J Clin Pharmacol; 2023 Apr; 63(4):421-434. PubMed ID: 36374235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
